Patient characteristics and distribution
| CRS groups | CRS-1,N=82(40.8%) | CRS-2,N=65(32.3%) | CRS-3,N=54(26.9%) |
|---|---|---|---|
| Number of NaCT cycles | 3 cycles,n=48(23.9%) | 4 cycles,n=136(67.7%) | Greater than 4 cycles n=17(8.4%) |
| Extent of cytoreduction | Complete n=77(38.3%) | Optimal n=100(49.7%) | Suboptimal n=24(12%) |
| Radiological response | Good response n=88(43.8%) | Partial response n=82(40.8%) | Poor response n=31(15.4%) |
| Stages | III C n=113(56%) | IV A n=37(18%) | IV B n=47(23%) |
| Histology | HGSC n=187(93%) | Other histology n=14(7%) | |
| Type of NaCT | 3 weekly carbo/taxol n=189(94%) | weekly carbo/taxol n=12 | carbo/taxol/bevacizumab n=10 |